Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Platinum × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Carcinoma, Non-Small-Cell Lung 9 Small Cell Lung Carcinoma 8 Oropharyngeal Neoplasms 8 Mouth Neoplasms 7 Laryngeal Neoplasms 7 Carcinoma 7 Uterine Cervical Neoplasms 6 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 6 Nasopharyngeal Carcinoma 6 Hypopharyngeal Neoplasms 6 Triple Negative Breast Neoplasms 5 Mesothelioma, Malignant 4 Breast Neoplasms 4 Stomach Neoplasms 3 Salivary Gland Neoplasms 3 Prostatic Neoplasms 3 Medulloblastoma 3 Lymphoid Interstitial Pneumonia 3 Ganglioneuroblastoma 3 Fallopian Tube Neoplasms 3 Colorectal Neoplasms 3 Paranasal Sinus Neoplasms 2 Pancreatic Neoplasms 2 Neuroblastoma 2 Gallbladder Neoplasms 2 Carcinoma, Transitional Cell 2 Brain Neoplasms 2

Interventions

Cyclophosphamide 38 Dexamethasone 31 venetoclax 28 fludarabine 27 pembrolizumab 20 pomalidomide 17 Rituximab 17 Gemcitabine 16 Lenalidomide 14 Cytarabine 14 carfilzomib 11 Nivolumab 11 fludarabine phosphate 10 Temozolomide 10 Etoposide 10 Calcium Dobesilate 10 Azacitidine 10 glofitamab 9 daratumumab 9 Injections 9 obinutuzumab 8 Cisplatin 8 ibrutinib 7 cemiplimab 7 Carboplatin 7 Capecitabine 7 Bevacizumab 7 zanubrutinib 6 selinexor 6 ruxolitinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07097948 2025-08-01

Adjuvant

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡